Literature DB >> 19659459

Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

Ying Liu1, Fei Liu, Inge Grundke-Iqbal, Khalid Iqbal, Cheng-Xin Gong.   

Abstract

Type 2 diabetes mellitus (T2DM) increases the risk for Alzheimer's disease (AD), but the underlying mechanism is unknown. In this study, we determined the levels of major brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in the postmortem brain tissue from frontal cortices of 7 controls, 11 T2DM subjects, 10 AD subjects and 8 additional subjects who had both T2DM and AD. We found that the neuronal glucose transporter 3 was decreased to a bigger extent in T2DM brain than in AD brain. The O-GlcNAcylation levels of global proteins and of tau were also decreased in T2DM brain as seen in AD brain. Phosphorylation of tau at some of the AD abnormal hyperphosphorylation sites was increased in T2DM brain. These results suggest that T2DM may contribute to the increased risk for AD by impairing brain glucose uptake/metabolism and, consequently, down-regulation of O-GlcNAcylation, which facilitates abnormal hyperphosphorylation of tau.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659459      PMCID: PMC2760012          DOI: 10.1111/j.1471-4159.2009.06320.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

Review 1.  Expression, regulation, and functional role of glucose transporters (GLUTs) in brain.

Authors:  Donard S Dwyer; Susan J Vannucci; Ian A Simpson
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

Review 2.  Glucose transporter expression in the central nervous system: relationship to synaptic function.

Authors:  Bruce S McEwen; Lawrence P Reagan
Journal:  Eur J Pharmacol       Date:  2004-04-19       Impact factor: 4.432

3.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

4.  Assay of proteins in the presence of interfering materials.

Authors:  A Bensadoun; D Weinstein
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

5.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

Authors:  Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Gerald W Hart; Cheng-Xin Gong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease.

Authors:  I A Simpson; K R Chundu; T Davies-Hill; W G Honer; P Davies
Journal:  Ann Neurol       Date:  1994-05       Impact factor: 10.422

7.  Pseudophosphorylation of tau protein alters its ability for self-aggregation.

Authors:  C Haase; J T Stieler; T Arendt; M Holzer
Journal:  J Neurochem       Date:  2004-03       Impact factor: 5.372

8.  Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding.

Authors:  J Biernat; N Gustke; G Drewes; E M Mandelkow; E Mandelkow
Journal:  Neuron       Date:  1993-07       Impact factor: 17.173

9.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

Authors:  Fei Liu; Jianhua Shi; Hitoshi Tanimukai; Jinhua Gu; Jianlan Gu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Brain       Date:  2009-05-18       Impact factor: 13.501

10.  Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease.

Authors:  R N Kalaria; S I Harik
Journal:  J Neurochem       Date:  1989-10       Impact factor: 5.372

View more
  62 in total

1.  Diverse regulation of AKT and GSK-3β by O-GlcNAcylation in various types of cells.

Authors:  Jianhua Shi; Shiliang Wu; Chun-ling Dai; Yi Li; Inge Grundke-Iqbal; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  FEBS Lett       Date:  2012-06-08       Impact factor: 4.124

Review 2.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.

Authors:  Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 3.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

4.  mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice.

Authors:  Shan Wang; Shan-lei Zhou; Fang-yuan Min; Jin-ju Ma; Xia-jie Shi; Erika Bereczki; Jing Wu
Journal:  Metab Brain Dis       Date:  2014-03-30       Impact factor: 3.584

5.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

6.  Diabetes-induced abnormalities of mitochondrial function in rat brain cortex: the effect of n-3 fatty acid diet.

Authors:  Maria Chomova; Maria Balazova; Jana Muchova
Journal:  Mol Cell Biochem       Date:  2017-05-19       Impact factor: 3.396

7.  Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.

Authors:  Erika J Starks; J Patrick O'Grady; Siobhan M Hoscheidt; Annie M Racine; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Luigi Puglielli; Sanjay Asthana; N Maritza Dowling; Carey E Gleason; Rozalyn M Anderson; Nancy J Davenport-Sis; LeAnn M DeRungs; Mark A Sager; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

Authors:  Scott A Yuzwa; Xiaoyang Shan; Matthew S Macauley; Thomas Clark; Yuliya Skorobogatko; Keith Vosseller; David J Vocadlo
Journal:  Nat Chem Biol       Date:  2012-02-26       Impact factor: 15.040

Review 9.  Deregulation of brain insulin signaling in Alzheimer's disease.

Authors:  Yanxing Chen; Yanqiu Deng; Baorong Zhang; Cheng-Xin Gong
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

10.  Word-stem priming and recognition in type 2 diabetes mellitus, Alzheimer's disease patients and healthy older adults.

Authors:  María Teresa Redondo; José Luís Beltrán-Brotóns; José Manuel Reales; Soledad Ballesteros
Journal:  Exp Brain Res       Date:  2015-08-08       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.